Borgeson Blake sold $158K of RXRX
Borgeson Blake sold 40,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.96 ($0.16M total) on 2026-07-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides transparency on insider selling activity but does not report any new business development, financial result, or regulatory event.
Market read
Primarily a sentiment/positioning datapoint; likely not a standalone catalyst for RXRX price action.
What to watch
Traders may over-weight insider sales; without accompanying buys, guidance changes, or clinical/regulatory updates, the informational content is limited.
Background
The article is a SEC Form 4 insider transaction disclosure for Recursion Pharmaceuticals, Inc.
Ticker impact
Recursion Pharmaceuticals director Borgeson Blake filed a Form 4 selling 40,000 shares at $3.9625 on 2026-07-07 under a 10b5-1 plan.
Likely limited near-term impact; any effect is more about sentiment than fundamentals.
The filing is an open-market sale by a director, explicitly tied to a pre-arranged Rule 10b5-1 plan, and contains no new company-specific performance or guidance information.
Market effects
Minimal; insider sale does not introduce a sector-wide signal.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerRecursion Pharmaceuticals, Inc.
Company whose director sold shares via an open-market transaction under a Rule 10b5-1 plan.
- insiderBorgeson Blake
Director who sold 40,000 shares at $3.9625 on 2026-07-07.
